Related Experiment Video
Updated: Jul 14, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines
Karolina Wojtowicz1, Monika Świerczewska1, Michał Nowicki1
1Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland.
Purpose:
The primary limiting factor in achieving cures for patients with cancer, particularly ovarian cancer, is drug resistance. The mechanisms of drug resistance of cancer cells during chemotherapy may include compounds of the extracellular matrix, such as the transforming growth factor-beta-induced protein (TGFBI). In this study, we aimed to analyze the TGFBI gene and protein expression in different sensitive and drug-resistant ovarian cancer cell lines, as well as test if TGFBI can be involved in the response to topotecan (TOP) at the very early stages of treatment.
Materials And Methods:
In this study, we conducted a detailed analysis of TGFBI expression in different ovarian cancer cell lines (A2780, A2780TR1, A2780TR2, W1, W1TR, SKOV-3, PEA1, PEA2 and PEO23). The level of TGFBI mRNA (QPCR), intracellular and extracellular protein (Western blot analysis) were assessed in this study.
Results:
We observed upregulation of TGFBI mRNA in drug-resistant cell lines and estrogen-receptor positive cell lines, which was supported by overexpression of both intracellular and extracellular TGFBI protein. We also showed the TGFBI expression after a short period of treatment of sensitive ovarian cancer cell lines with TOP.
Conclusion:
The expression of TGFBI in ovarian cancer cell lines suggests its role in the development of drug resistance.
Insights
Transforming growth factor-beta-induced protein (TGFBI) is upregulated in drug-resistant ovarian cancer cells. This suggests TGFBI plays a role in chemotherapy resistance, impacting treatment effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Drug resistance is a major obstacle in cancer treatment, particularly for ovarian cancer.
- The extracellular matrix, including transforming growth factor-beta-induced protein (TGFBI), may contribute to cancer cell drug resistance mechanisms.
Purpose of the Study:
- To analyze gene and protein expression of TGFBI in sensitive and drug-resistant ovarian cancer cell lines.
- To investigate TGFBI's potential involvement in the early response to topotecan (TOP) chemotherapy.
Main Methods:
- Analysis of TGFBI mRNA levels using quantitative PCR (QPCR).
- Assessment of intracellular and extracellular TGFBI protein levels via Western blot analysis.
- Evaluation of TGFBI expression in various ovarian cancer cell lines (A2780, A2780TR1, A2780TR2, W1, W1TR, SKOV-3, PEA1, PEA2, PEO23).
Main Results:
- TGFBI mRNA was upregulated in drug-resistant and estrogen-receptor positive ovarian cancer cell lines.
- Overexpression of both intracellular and extracellular TGFBI protein was observed in resistant cell lines.
- TGFBI expression was detected in sensitive ovarian cancer cell lines following short-term topotecan treatment.
Conclusions:
- TGFBI expression in ovarian cancer cell lines indicates its involvement in the development of drug resistance.
- Findings suggest TGFBI as a potential biomarker or therapeutic target for overcoming chemotherapy resistance in ovarian cancer.
Related Concept Videos
02:56Treatment Resistant Cancers
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...